Compare, Analyse Aurobindo Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-21
ADCOCK INGRAM
Jun-14
AUROBINDO PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs1,023344-   
Low Rs333248-   
Sales per share (Unadj.) Rs422.8102.2-  
Earnings per share (Unadj.) Rs92.0-25.8-  
Cash flow per share (Unadj.) Rs110.0-21.3-  
Dividends per share (Unadj.) Rs4.000-  
Avg Dividend yield %0.60-  
Book value per share (Unadj.) Rs374.380.2-  
Shares outstanding (eoy) m585.94168.78-   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.62.9 55.4%   
Avg P/E ratio x7.4-11.5 -64.2%  
P/CF ratio (eoy) x6.2-13.9 -44.5%  
Price / Book Value ratio x1.83.7 49.2%  
Dividend payout %4.30-   
Avg Mkt Cap Rs m397,39849,921 796.1%   
No. of employees `000NA4.3 0.0%   
Total wages/salary Rs m35,3503,133 1,128.3%   
Avg. sales/employee Rs ThNM4,019.0-  
Avg. wages/employee Rs ThNM729.8-  
Avg. net profit/employee Rs ThNM-1,012.7-  
INCOME DATA
Net Sales Rs m247,74617,254 1,435.9%  
Other income Rs m3,809121 3,152.1%   
Total revenues Rs m251,55517,374 1,447.8%   
Gross profit Rs m81,480-2,990 -2,725.1%  
Depreciation Rs m10,554745 1,417.3%   
Interest Rs m745467 159.4%   
Profit before tax Rs m73,990-4,081 -1,813.0%   
Minority Interest Rs m0-11 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m20,098255 7,881.1%   
Profit after tax Rs m53,892-4,348 -1,239.6%  
Gross profit margin %32.9-17.3 -189.8%  
Effective tax rate %27.2-6.2 -434.7%   
Net profit margin %21.8-25.2 -86.3%  
BALANCE SHEET DATA
Current assets Rs m198,23512,637 1,568.7%   
Current liabilities Rs m106,6527,110 1,500.0%   
Net working cap to sales %37.032.0 115.4%  
Current ratio x1.91.8 104.6%  
Inventory Days Days19111 17.3%  
Debtors Days Days52124 41.6%  
Net fixed assets Rs m135,7787,366 1,843.3%   
Share capital Rs m58680 731.4%   
"Free" reserves Rs m218,7130-   
Net worth Rs m219,29913,542 1,619.4%   
Long term debt Rs m1,6844,759 35.4%   
Total assets Rs m334,01325,582 1,305.6%  
Interest coverage x100.3-7.7 -1,297.5%   
Debt to equity ratio x00.4 2.2%  
Sales to assets ratio x0.70.7 110.0%   
Return on assets %16.4-15.2 -107.8%  
Return on equity %24.6-32.1 -76.5%  
Return on capital %33.8-19.8 -170.7%  
Exports to sales %53.80-   
Imports to sales %16.40-   
Net fx Rs m88,3020-   
CASH FLOW
From Operations Rs m33,2891,473 2,260.4%  
From Investments Rs m5,987-452 -1,324.0%  
From Financial Activity Rs m-13,6484,319 -316.0%  
Net Cashflow Rs m25,8315,340 483.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 4.74 Rs / ZAR

Compare AUROBINDO PHARMA With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: FREDUN PHARMA  BIOFIL CHEMICALS  WINDLAS BIOTECH  KABRA DRUGS  PANACEA BIOTECH  



Today's Market

FabIndia IPO, Tanla Platforms' Partnership with Vodafone Idea, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a strong note yesterday. Benchmark indices snapped two days of losses and witnessed sharp gains as globally fears of a significant impact on economic.

Related Views On News

AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (down 2.0% YoY). Sales on the other hand came in at Rs 57 bn (down 3.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Aug 9, 2021 | Updated on Aug 9, 2021

Here's an analysis of the annual report of AUROBINDO PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles (Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

7 Stocks that Mutual Funds Can't get Enough of (Views On News)

Dec 1, 2021

Come hell or high water, these are the top Indian stocks which mutual funds never leave.

More
-->

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2022
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: How to Profit from Sensex 100,000
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

AUROBINDO PHARMA SHARE PRICE


Dec 7, 2021 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS